UGCG and Fabry disease: Targeting UGCG has demonstrated efficacy in treating rare genetic disorders such as Gaucher disease [20, 21], for which eliglustat has been approved, and Fabry disease, for which ibiglustat is currently under clinical evaluation (NCT02228460 and NCT2489344).